Pre-validated pharmaceutical water, industrial membrane separation, and seawater RO generation units built to current pharmacopeial thresholds.
Analysis of USP <1231>, EP 10, JP XVII harmonization and the industrial shift toward membrane-based Water for Injection generation.
Global manufacturing facilities operating under US FDA, EMA, or NMPA scrutiny demand unified Purified Water (PW) and Water for Injection (WFI) architectures. The revisions in European Pharmacopoeia (EP) enabling non-thermal, membrane-based WFI generation—aligning directly with USP standards—have triggered a massive industrial shift toward multi-stage RO coupled with continuous electrodeionization (CEDI) and ultrafiltration.
Traditional multi-effect distillation systems demand excessive thermal energy and cooling water volumes. Modern wholesale buyers prioritize skid-mounted, ambient-temperature membrane trains that drop operating expenditure (OPEX) by up to 65%. Systems incorporating physical degassing membranes eliminate the need for thermal degassing towers, optimizing space and footprint while slashing thermal greenhouse signatures.
The transition from off-line grab sampling to real-time release testing (RTRT) necessitates integrated instrumentation: non-dispersive infrared TOC sensors, temperature-compensated electrolytic conductivity meters, and autonomous ozone/thermal sanitization monitoring. Process traceability down to 0.1 ppb TOC ensures total conformity with FDA 21 CFR Part 11 electronic records protocols.
Multi-barrier process engineering designed to eliminate dead legs, biological biofilm development, and mineral scaling across pharmaceutical facilities.
Configured with automated backwash multimedia filters, activated carbon filtration (ACF) beds with hot-water sanitization capability, and duplex alternating water softeners. Raw feed water hardness, suspended solids, and free chlorine (reduced to <0.05 ppm) are mitigated to safeguard downstream polyamide composite reverse osmosis membranes from premature oxidation and colloidal deposition.
Our dual-pass reverse osmosis skids utilize premium spiral-wound polyamide elements arranged in staged arrays to maximize recovery (typically 75–85%). Incorporated hollow-fiber contactor membrane degassing extracts dissolved CO2 down to <2 ppm, drastically relieving ionic loading on downstream EDI stacks without requiring chemical sodium hydroxide dosing.
Hermetically sealed, chemical-free polishing modules continuously electro-regenerate mixed-bed ion-exchange resins. Delivering constant effluent resistivity between 15.0 and 18.2 MΩ·cm, the CEDI array avoids batch exhaustion cycles, guarantees continuous TOC reduction (<50 ppb), and complies fully with USP Purified Water quality without handling hazardous acids and caustics.
| Analytical Parameter | USP Purified Water (PW) | USP / EP Water for Injection (WFI) | Tongjie Engineered Factory Standard |
|---|---|---|---|
| Conductivity @ 25°C | ≤ 1.3 μS/cm (Stage 1 inline) | ≤ 1.3 μS/cm (Stage 1 inline) | 0.06 – 0.5 μS/cm (Continuous CEDI) |
| Total Organic Carbon (TOC) | < 500 μg/L (ppb) | < 500 μg/L (ppb) | ≤ 20 – 100 μg/L (Inline NDIR) |
| Bacterial Endotoxins | Not specified (typically <0.25 EU/mL) | < 0.25 EU/mL | ≤ 0.03 EU/mL (Post-UF barrier) |
| Microbial Enumeration (TVC) | ≤ 100 CFU / mL | ≤ 10 CFU / 100 mL | < 1 CFU / 100 mL (System Design) |
| Wetted Materials & Roughness | AISI 316L / PVDF | AISI 316L (Ra ≤ 0.51 μm, Electropolished) | SS316L Orbital Welded (Ra ≤ 0.38 μm) |
Complete regulatory lifecycle documentation designed to survive stringent FDA, WHO, and national inspectorate scrutiny.
Every industrial unit leaves Shanghai Tongjie complete with full validation documentation. Includes Functional Design Specification (FDS), factory calibration certificates for every analog transducer, weld inspection logs, and endoscopy video mapping.
High-purity distribution skids are fabricated from AISI 316L stainless steel utilizing closed-chamber automatic orbital TIG welding with high-purity argon shielding. 100% weld traceability and borescope video logs ensure total exclusion of rouge and heat tints.
Control panels powered by Siemens S7-1500 or Allen-Bradley PACs feature non-alterable audit trails, multi-level biometric or smartcard access control, electronic signatures, and historical process trending recorded to encrypted databases for effortless data integrity audits.
Hydraulic distribution systems and diaphragm valves are engineered to comply strictly with ISPE Baseline Guide Volume 4 and ASME BPE rules. Zero-dead-leg block valves and strict L/D ratios below 1.5 ensure turbulent cleaning flow and suppress sessile biofilm attachment.
Strategic technological initiatives advancing membrane longevity, energy recovery efficiency, and zero liquid discharge closed loops.
Addressing hypersaline API discharge by breaking through traditional hydraulic osmotic pressure limits. By utilizing low-salinity sweep brines across staged semi-permeable membranes, OARO concentrates TDS streams beyond 180,000 mg/L at conventional operating pressures (80–120 bar), cutting thermal crystallizer energy consumption by over 40%.
By monitoring differential pressure (ΔP), flux normalized decline, and temperature profiles in real time through machine learning inference models, our PLC systems initiate targeted chemical-in-place (CIP) or hot-water sanitization before irreversible biofouling or salt precipitation develops, extending membrane lifespan to 5+ years.
Integrating customized Disc Tube Reverse Osmosis (DTRO) and 6000 Da molecular weight cut-off (MWCO) tubular ultrafiltration elements to reliably reject bacterial endotoxins down to <0.005 EU/mL without steam phase transformation. Compliant with updated EP/USP standards for sterile parenteral drug manufacturing.
In-depth technical answers addressing user requirements specifications (URS), sanitization regimes, and regulatory adherence.
Industrial brine concentration, degasification units, and electronic-grade pure water systems for global export.